CN Patent

CN106674319B — 一种治疗丙肝的化合物

Assigned to Brightgene Bio Medical Technology Co Ltd · Expires 2020-04-21 · 6y expired

What this patent protects

本发明公开了一种如下式所示的化合物或其可药用盐：本发明所公开的化合物，具有优于索非布韦的治疗丙肝的效果，且毒副作用与索非布韦类似，并无明显的不良反应。

USPTO Abstract

本发明公开了一种如下式所示的化合物或其可药用盐：本发明所公开的化合物，具有优于索非布韦的治疗丙肝的效果，且毒副作用与索非布韦类似，并无明显的不良反应。

Drugs covered by this patent

Patent Metadata

Patent number: CN106674319B
Jurisdiction: CN
Classification: —
Expires: 2020-04-21
Drug substance claim: No
Drug product claim: No
Assignee: Brightgene Bio Medical Technology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.